1. Home
  2. APLM vs SRXH Comparison

APLM vs SRXH Comparison

Compare APLM & SRXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • APLM
  • SRXH
  • Stock Information
  • Founded
  • APLM 2016
  • SRXH 2013
  • Country
  • APLM United States
  • SRXH Canada
  • Employees
  • APLM N/A
  • SRXH N/A
  • Industry
  • APLM Blank Checks
  • SRXH
  • Sector
  • APLM Finance
  • SRXH
  • Exchange
  • APLM Nasdaq
  • SRXH NYSE
  • Market Cap
  • APLM 6.9M
  • SRXH 7.4M
  • IPO Year
  • APLM N/A
  • SRXH N/A
  • Fundamental
  • Price
  • APLM $6.06
  • SRXH $0.55
  • Analyst Decision
  • APLM
  • SRXH
  • Analyst Count
  • APLM 0
  • SRXH 0
  • Target Price
  • APLM N/A
  • SRXH N/A
  • AVG Volume (30 Days)
  • APLM 28.0K
  • SRXH 573.1K
  • Earning Date
  • APLM 08-13-2025
  • SRXH 05-15-2025
  • Dividend Yield
  • APLM N/A
  • SRXH N/A
  • EPS Growth
  • APLM N/A
  • SRXH N/A
  • EPS
  • APLM N/A
  • SRXH N/A
  • Revenue
  • APLM $198,000.00
  • SRXH $119,421,918.00
  • Revenue This Year
  • APLM $415.15
  • SRXH $26.28
  • Revenue Next Year
  • APLM N/A
  • SRXH $25.00
  • P/E Ratio
  • APLM N/A
  • SRXH N/A
  • Revenue Growth
  • APLM N/A
  • SRXH 26.27
  • 52 Week Low
  • APLM $4.47
  • SRXH $0.47
  • 52 Week High
  • APLM $35.98
  • SRXH $4.24
  • Technical
  • Relative Strength Index (RSI)
  • APLM 48.70
  • SRXH N/A
  • Support Level
  • APLM $5.11
  • SRXH N/A
  • Resistance Level
  • APLM $6.56
  • SRXH N/A
  • Average True Range (ATR)
  • APLM 0.49
  • SRXH 0.00
  • MACD
  • APLM 0.00
  • SRXH 0.00
  • Stochastic Oscillator
  • APLM 63.42
  • SRXH 0.00

About APLM Apollomics Inc.

Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.

About SRXH SRX HEALTH SOLUTIONS INC

SRX HealthSolutions Inc is an integrated, Canadian healthcare service provider operating within the specialty healthcare industry. It has developed a collaborative specialty healthcare network (the SRx Network) that strategically positions SRx to achieve business objectives. The SRx Network is comprised of 29 specialty pharmacies, 40 infusion clinics and injection sites, four clinical trials sites, patient support programs (PSP), an allied health team and nursing services, and a wholly owned Health Canada-accredited pharmaceutical wholesale and distribution facility located in Mississauga, Ontario. The SRx Network extends across all 10 Canadian provinces, making it one of the accessible providers of comprehensive, integrated and customized specialty healthcare services in Canada.

Share on Social Networks: